Peak Human
    Clinical Evidence Review

    Hyperbaric Oxygen Therapy in 2026: What the Newest Trials Actually Show

    Reviewed by Dr. Sanjeev GoelJuly 13, 20269 min read

    The evidence base for hyperbaric oxygen therapy (HBOT) continues to mature across neurology, wound care, and longevity medicine. This practitioner-focused review summarizes six recent, credible studies — with protocols and effect sizes — so clinicians can weigh where the signal is strongest and where the data remain preliminary.

    Book an HBOT consultation at Peak Human

    Why tissue oxygenation is having a clinical moment

    HBOT delivers 100% oxygen at pressures above one atmosphere absolute (ATA), dramatically raising oxygen dissolved in plasma. Beyond correcting hypoxia, repeated sessions act as a controlled hyperoxic–hypoxic stimulus — transiently fluctuating oxygen tension to trigger regenerative signaling, angiogenesis, and mitochondrial adaptation. That mechanism is now being tested in progressively better-designed trials.

    "The most consistent, high-quality signal remains in wound healing — but neurocognitive and longevity applications are where the newest, most provocative data are emerging."
    Wound Care

    1. Diabetic foot ulcers: the strongest evidence

    An updated RCT meta-analysis found adjunctive HBOT increased ulcer healing (RR ≈ 1.90) and reduced major amputation (RR ≈ 0.52) versus standard care. Pooled complete-healing was ~46.8% with HBOT vs 24.5% without; major amputation fell from ~45% to ~26%. Protocols clustered around 2.0–2.5 ATA, 90-min sessions, 20–40 exposures. Benefit was clearest in Wagner grade III–IV ulcers with adequate perfusion.[1]

    Figure 1

    Diabetic foot ulcer outcomes: HBOT vs standard care

    Complete healing rate (higher is better) and major amputation rate (lower is better).[1]

    Longevity

    2. Longevity & immunosenescence: telomeres and senescent cells

    In a prospective trial of 35 adults aged 64+, 60 daily sessions at 2.0 ATA (90 min, 5 days/week) produced telomere elongation >20% in immune cells, a 37.3% drop in senescent T-helper cells, and an ~11% reduction in senescent cytotoxic T-cells. It was single-arm and uncontrolled — hypothesis-generating, not definitive.[2]

    Figure 2

    Cellular aging markers after 60 HBOT sessions

    Percent change from baseline in immune cells of older adults.[2]

    See if HBOT fits your protocol
    Neurocognition

    3. Post-COVID cognition: a sham-controlled RCT

    A randomized, double-blind, sham-controlled trial in 73 patients with post-COVID cognitive symptoms (HBOT arm: 40 sessions, 2.0 ATA, 90 min) showed significant gains in global cognitive function, attention, and executive function, with measurable brain perfusion and microstructure changes on imaging.[3]

    Neurology

    4. Traumatic brain injury: better trials underway

    A 2026 protocol describes a blinded, three-stage group-sequential RCT in veterans and service members with chronic mild-to-moderate TBI versus sham.[4] Alongside it, a 2025 retrospective cohort reported cognitive gains in adults with post-concussion symptoms from childhood TBI.[5] Sham-controlled TBI results are still maturing.

    Burn Care

    5. Burn care: adjunctive, not standalone

    A 2026 systematic review pooling 13 studies (5 RCTs, ~566 patients) found trends toward reduced surgical need, shorter hospital stays, and lower infection risk, with inconsistent mortality effects. HBOT is best positioned as a supportive adjunct, not a replacement for standard burn care.[6]

    Study snapshot
    IndicationDesignProtocolSignal
    Diabetic foot ulcerRCT meta-analysis2.0–2.5 ATA · 20–40 sessionsHealing RR 1.90 · amputation RR 0.52
    Aging / immunosenescenceProspective n=352.0 ATA · 60 sessionsTelomeres +20% · senescent T-helpers −37%
    Post-COVID cognitionSham RCT n=732.0 ATA · 40 sessions↑ cognition, attention, executive function
    Chronic TBIBlinded RCT protocolSham-controlledUnderway
    Burn careSystematic review (13 studies)AdjunctiveFewer surgeries · shorter stays

    Safety & contraindications

    HBOT is generally well tolerated. The most common adverse event is barotraumatic ear discomfort; less common events include transient myopia, rare oxygen-toxicity seizures, and confinement anxiety. Untreated pneumothorax is an absolute contraindication; caution is warranted with certain chemotherapy agents, severe COPD with air trapping, and recent ear surgery.

    Takeaways
    • Strongest evidence: diabetic foot ulcer healing and amputation prevention.
    • Emerging / promising: post-COVID cognition (sham-controlled) and chronic TBI (maturing).
    • Preliminary: longevity and telomere effects (uncontrolled).
    • Protocols cluster around 2.0–2.5 ATA, 90-min sessions, 20–60 exposures.
    • Position HBOT as an adjunct within an individualized plan.

    Educational only, reflects current peer-reviewed research (several findings preliminary); not medical advice. Decisions about HBOT should be made with a qualified healthcare provider.

    Talk to the Peak Human team about HBOT

    References

    1. [1]Efficacy of HBOT for diabetic foot ulcers: updated systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/34376365/
    2. [2]Hachmo Y, Hadanny A, et al. HBOT increases telomere length and decreases immunosenescence: a prospective trial. Aging, 2020. https://pubmed.ncbi.nlm.nih.gov/33206062/
    3. [3]Zilberman-Itskovich S, et al. HBOT improves neurocognitive functions and symptoms of post-COVID condition: RCT. Sci Rep, 2022. https://pubmed.ncbi.nlm.nih.gov/35821512/
    4. [4]Efficacy of HBOT in veterans/service members with TBI — study protocol, blinded three-stage group sequential RCT. 2026. https://pubmed.ncbi.nlm.nih.gov/41882764/
    5. [5]HBOT improves post-concussion symptoms in adults with childhood TBI: retrospective cohort. Front Neurol, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12440767/
    6. [6]HBOT in burn care: a systematic review of current evidence. 2026. https://pubmed.ncbi.nlm.nih.gov/41700783/